Potential role of muscarinic agonists in Alzheimer's disease

Drugs and Aging

Volumn 11, Issue 6, 1997, Pages 450-459

  Avery, Eleanor E ^b   Baker, Laura D ^b   Asthana, Sanjay ^a  

^a VA PUGET SOUND HEALTH CARE SYSTEM   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

2 ETHYL 8 METHYL 2,8 DIAZASPIRO[4.5]DECANE 1,3 DIONE; 3 (6 CHLORO 2 PYRAZINYL)QUINUCLIDINE; 3 [3 (3 METHOXYPHENYL) 2 PROPYNYLOXYIMINO] 1 AZABICYCLO[2.2.1]HEPTANE; ACETYLCHOLINE; ACETYLCHOLINE DERIVATIVE; ALKALOID; ALVAMELINE; AMYLOID PRECURSOR PROTEIN; ARECOLINE; BETHANECHOL; BIMC 182; BRAIN RECEPTOR; CEVIMELINE; CHOLINESTERASE INHIBITOR; DONEPEZIL; MILAMELINE; MUSCARINIC AGENT; MUSCARINIC M1 RECEPTOR; MUSCARINIC M2 RECEPTOR; MUSCARINIC RECEPTOR; OXOTREMORINE; PD 142505; PHYSOSTIGMINE; POSTSYNAPTIC RECEPTOR; PRESYNAPTIC RECEPTOR; SABCOMELINE; SCOPOLAMINE; TACRINE; UNCLASSIFIED DRUG; XANOMELINE;

ACETYLCHOLINE RELEASE; ADVERSE DRUG REACTION; ALZHEIMER DISEASE; CHOLINERGIC NERVE CELL; CLINICAL TRIAL; COGNITION; DEPRESSION; DRUG ELIMINATION; DRUG HALF LIFE; FOREBRAIN; HUMAN; INTRACEREBRAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; NERVE DEGENERATION; NEUROFIBRILLARY TANGLE; NEUROPATHOLOGY; NEUROTOXICITY; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; REVIEW;

EID: 0030734590     PISSN: 1170229X     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002512-199711060-00004     Document Type: Review

References (92)

1. Cummings J, Benson D, Dementia: a clinical approach. Boston: Butterworth-Heinemann, 1992
2. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, fourth edition (DSM-IV). Washington, DC: American Psychiatric Association, 1994
3. Pendlebury WW, Solomon PR. Alzheimer's disease. In: Bean K, editor. Clinical symposia. Vol. 48. Summit (NJ): Ciba-Geigy Corporation, 1996: 2-31
4. Rice DP, Fox PJ, Max W, et al. The economic burden of Alzheimer's disease care. Health Aff 1993; 12: 164-76
5. Bodick N, Offen W, Levey A, et al. Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer's disease. Arch Neurol 1997; 54: 465-73
6. Knapp M, Knopman D, Solomon P, et al. A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease. JAMA 1994; 271: 985-91
7. Cummings JL, Kaufer D. Neuropsychiatric aspects of Alzheimer's disease, the cholinergic hypothesis revisited. Neurology 1996; 47: 876-83
8. Bartus R, Dean R, Beer B, et al. The cholinergic hypothesis of geriatric memory dysfunction. Science 1982; 217: 408-17
9. Weinstock M. The pharmacology of Alzheimer's disease based on the cholinergic hypothesis: an update. Neurodegeneration 1995; 4: 349-56
10. Cowburn RF, Fowler CJ, O'Neill C. Neurotransmitters, signal transduction and second-messengers in Alzheimer's disease. Acta Neurol Scand 1996; 93 Suppl. 165: 25-32
11. Whitehouse PJ, Price DL, Clark AW, et al. Alzheimer's disease: evidence for selective loss of cholinergic neurons in nucleus hasalis. J Neuropathol Exp Neurol 1981; 10: 122-6
12. Johns C, Haroutunian V, Greenwald BS, et al. Development of cholinergic drugs for the treatment of Alzheimer's disease. Drug Dev Res 1985; 5: 77-96
13. Ehlert FJ, Roeske WR, Yamamura HI. Muscarinic receptors and novel strategies for the treatment of age-related brain disorders. Life Sci 1994; 55; 2135-45
14. Davis K, Mohs R, Tinklenberg J, et al. Physostigmine: improvement of long-term memory processes in normal humans. Science 1978; 201: 272-4
15. Hollander E, Davidson M, Mohs R, et al. RS 86 in the treatment of Alzheimer's disease: cognitive and biological effects. Biol Psychiatry 1987; 22: 1067-8
16. Soncrant TT, Raffaele KC, Asthana S, et al. Memory improvement without toxicity during chronic low-dose intravenous arecoline in Alzheimer's disease. Psychopharmacology 1993; 112: 421-7
17. Tariot P, Cohen R, Welkowitz J, et al. Multiple dose arecoline infusions in Alzheimer's disease. Arch Gen Psychiatry 1988; 45: 901-5
18. Davis K, Hollander E, Davidson M, et al. Induction of depression with oxotremorine in Alzheimer's disease patients. Am J Psychiatry 1987; 144: 468-71
19. Penn R, Martin E, Wilson R, et al. Intraventricular bethanechol infusion of Alzheimer's disease: results of double blind and escalating dose trials. Neurology 1988; 38: 219-22
20. Mouradian M, Mohr E, Williams A, et al. No response to high-dose muscarinic agonist therapy in Alzheimer's disease. Neurology 1988; 38: 606-8
21. Quirion R, Martel JC, Robitaille Y, et al. Neurotransmitters and receptor deficits in senile dementia of the Alzheimer's type. Can J Neurol Sci 1986; 13: 503-10
22. Giacohini E, DeSarno P, Clark B, et al. The cholinergic receptor system of the human brain: neurochemical and pharmacological aspects in aging and Alzheimer's disease. Prog Brain Res 1989; 79: 335-43
23. Ogawa N, Mizukawa K, Asanuma M, et al. Abnormalities in muscarinic cholinergic receptors and their G-protein coupling systems in the cerebral frontal cortex in Alzheimer's disease. Arch Gerontol Geriatr 1993; 17: 77-89
24. Weinberger DR, Gibson R, Coppola R, et al. The distribution of cerebral muscarinic acetylcholine receptors in vivo in patients with dememia: a controlled study with 123IQNB and single photon emission computed tomography. Arch Neurol 1991; 48: 169-76
25. 1 muscarinic receptor-G protein coupling in Alzheimer's disease. J Neuropathol Exp Neurol 1995; 54: 783-9
26. Parent A, Rowe W, Meaney MJ, et al. Increased production of inosilol phosphates and diacylglycerol in aged cognitively impaired rats after stimulation of muscarinic, metabolropic-glutamate and endothelin receptors. J Pharmacol Exp Ther 1995; 272: 1110-6
27. Alder J, Chessell I, Bowen D. A neurochemical approach for studying response to acelylcholine in Alzheimer's disease. Neurochem Res 1995; 20: 769-71
28. McKinney M, Coyle JT. The potential for muscarinic receptor subtype-specific pharmacotherapy for Alzheimer's disease. Mayo Clin Proc 1991; 66: 1225-37
29. Nelson R, Friedman D, O'Neill J, et al. Gradients of protein kinase C substrate phosphorylation in primate visual system peak in visual memory storage areas. Brain Res 1987; 416: 387-92
30. Routtenberg A. Protein kinase C activation leading to protein F1 phosphorylation may regulate synaptic plasticity by presynaptic terminal growth. Behav Neurol Biol 1985; 44: 186-200
31. Erulkar S. Chemically mediated synaptic transmission: an overview. In: Siegel G, Agranoff B, Albers R, et al., editors. Basic neurochemistry. New York: Raven Press, 1989: 151-82
32. Davis R, Doyle P, Carroll R, et al. Cholinergic therapies for Alzheimer's disease: palliative or disease altering? Arzneimittel Forschung 1995; 45: 425-31
33. Cutler N, Sramek J. Muscurinic M1 receptor agonists: potential in the treatment of Alzheimer's disease. CNS Drugs 1995; 3 (6): 467-81
34. Raffaele KC, Asthana S, Berardi A, et al. Differential response to the cholinergic agonist arecoline among different cognitive modalities in Alzheimer's disease. Neuropsychopharmacology 1996; 15: 163-70
35. Wettstein A, Spiegel R. Clinical trials with the cholinergic drug RS 86 in Alzheimer's disease and senile dementia of the Alzheimer's type. Psychopharmacology 1984; 84: 572-3
36. Kumar R, Cedar E, Clark MS, et al. Muscarinic partial agonists in the symptomatic treatment of Alzheimer's disease. In: Becker R, Giacobini E, editors. Alzheimer disease: from molecular biology to therapy. Boston: Birkhauser, 1996: 299-303
37. Kumar R, Orgogozo J. Efficacy and safety of SB 202026 as a symptomatic treatment for Alzheimer disease [abstract]. Neurobiol Aging 1996; 17 Suppl. 4S: S161
38. Fisher A, Heldman E, Gurwitz D, et al. M1 agonists for the treatment of Alzheimer's disease: novel properties and clinical update. Ann N Y Acad Sci 1946; 777: 189-96
39. Rossor M. Molecular pathology of Alzheimer's disease. J Neurol Neurosurg Psychiatry 1993; 56: 583-6
40. Wolf BA, Wertkin AM, Jolly YC, et al. Muscarinic regulation of Alzheimer's disease amyloid precursor protein secretion and amyloid beta-protein production in human neuronal NT2N cells. J Biol Chem 1995; 270: 4916-22
41. Schehr RS. Therapeutic approaches to Alzheimer's disease: an informal survey of promising drug discovery strategies. Biotechnology 1994; 12: 140-4
42. Nitsch R, Slack B, Wurtman R, et al. Release of Alzheimer amyloid precursor derivatives stimulated by activation of muscarinic acetylcholine receptors. Science 1992; 258: 304-7
43. Buxhaum J, Oishi M, Chen H, et al. Cholinergic agonists and interleukin 1 regulate processing and secretion of the Alzheimer beta/A4 amyloid protein precursor. Proc Natl Acad Sci USA 1992; 89: 10075-8
44. Eckols K, Bymaster F, Mitch C, et al. The muscarinic M1 agonist xanomeline increases soluble amyloid precursor protein release from Chinese hamster ovary-m1 cells. Life Sci 1995; 57: 1183-90
45. Hung A, Haass C, Nitsch R, et al. Actuation of protein kinase C inhibits cellular production of the amyloid beta-protein. J Biol Chem 1993; 268: 22959-62
46. Siman R, Scott RW. Strategies to alter the progression of Alzheimer's disease. Curr Opin Biotechnol 1996; 7: 601-7
47. Fisher A, Haring R, Pittel Z, et al. Novel M1 agonists: from symptomatic treatment towards delaying the progression of Alzheimer's disease. In: Becker R, Giacobini F, editor. Alzheimer disease: from molecular biology to therapy. Boston: Birkhauser 1996: 317-22
48. Sadot E, Gurwitz D, Barg J, et al. Activation of M1-muscarinic acetylcholine receptor regulates tau phosphorylation in transfected PC12 cells. J Neurochem 1996; 66: 877-80
49. Pinkas-Kramarski R, Stein R, Barg J, et al. Growth factor-like effects mediated by muscarinic receptors in PC12M1 cells. J Neurochem 1992; 59: 2158-66
50. 1 muscarinic agonist, in PC12M1 cells. Neuroreport 1995; 6: 485-8
51. Mount H, Dreyfus C, Black I. Muscarinic stimulation promotes cultured Purkinje cell survival: a role for acetylcholine in cerebellar development? J Neurochem 1994; 63: 2065-73
52. Sitaram N, Weingartner H, Gillin J. Human serial learning: enhancement with arecoline and choline and impairment with scopolamine. Science 1978; 201: 274-6
53. Christie JE, Shering A, Ferguson J, et al. Physostigmine and arecoline: effects of intravenous infusions in Alzheimer presenile dementia. Br J Psychiatry 1981; 118: 46-50
54. Burton-Bradley BG. Arecaidinism: betel chewing in transcultural perspective. Can J Psychiatry 1479; 24. 481-8
55. Richards M. Relative potencies of agonists and differential sensitivity to N-ethylmaleimide on muscarinic antoreceptors and postsynaptic receptors in rat hippocampus. J Pharmacol Exp Ther 1990; 255: 83-9
56. Asthana S, Greig N, Holloway H, et al. Clinical pharmacokinetics of arecoline in subjects with Alzheimer's disease. Clin Pharmacol Ther 1195; 60: 276-82
57. Soncrant T, Holloway H, Greig N, et al. Regional brain metabolic responsivity to the muscarinic cholinergic agonist arecoline is similar in young and aged Fischer-344 rats. Brain Res 1989; 487: 255-66
58. Shetty H, Daly E, Greig N, et al. An automatic reaction control chemical ionization technique in ion trap detector for quantitative plasma profiling of arecoline in treated Alzheimer patients. J Am Soc Mass Spectrom 1991; 2: 168-73
59. Witkin JM. Central and peripheral muscarinic actions of physostigmine and oxotremorine on avoidance responding of squirrel monkeys. Psychopharmacology 1989; 97: 376-82
60. Bertrand N, Beley A. Effect of oxotremorine, physostigmine and scopolamine on brain acetylcholine synthesis: a study using HPLC. Neurochem Res 1990; 15: 1097-100
61. Baratti C, Huygens P, Mino J, et al. Memory facilitation with posttrial injection of oxotremorine and physostigmine in mice. Psychopharmacology 1979; 64: 85-8
62. Ukai M, Kobayashi T, Kameyama T. Characterization of the effects of scopolamine on the habituation of exploratory activity: differential effects of oxotremorine and physostigmine. Gen Pharmacol 1994; 25: 433-8
63. Winblad B, Messamore E, O'Neill C, et al. Biochemical pathology and treatment strategies in Alzheimer's disease: emphasis on the cholinergic system. Acta Neurol Scand 1993; 83 Suppl. 149: 4-6
64. Giacobini E, Becker R. Present progress and future development in the therapy for Alzheimer's disease. Proc Clin Biol Res 1989; 317: 1121-54
65. Davidson M, Stern R, Bierer L, et al. Cholinergic strategies in the treatment of Alzheimer's disease. Acta Psychiatr Scand 1991; 83 Suppl. 366: 47-51
66. Palacios JM, Boddeke HWGM, Pombo-Villar E. Cholinergic neuropharmacology: an update. Acta Psychiatr Scand 1991; 83 Suppl. 366: 27-33
67. Palacios J, Spiegel R. Muscarinic cholinergic agonists: pharmacologic and clinical perspectives. Prog Brain Res 1986; 70: 485-98
68. Volger BW. Alternatives in the treatment of memory loss in patients with Alzheimer's disease. Clin Pharm 1991; 10: 447-56
69. Davis R, Raby C, Callahan MJ, et al. Subtype selective muscarinic agonists: potential therapeutic agents for Alzheimer's disease. Prog Brain Res 1991; 98: 439-45
70. Callahan M. Combined treatment with tacrine and the muscarinic agonist CI-979 (RU 15 926) reverses a scopolamine-induced impairment of sustained attention in rhesus monkeys [abstract]. Soc Neurosci Abstr 1996; 22: 2121
71. Culler NR, Sramek JJ. The target population in phase I clinical trials of cholinergic compounds in Alzheimer disease: the role of the 'bridging study'. Alzheimer Dis Assoc Disord 1995; 9: 139-45
72. Sramek J, Sedman A, Reece P, et al. Safety and tolerability of CI-979 in patients with Alzheimer's disease. Life Sci 1995; 57: 503-10
73. 1 selective partial agonist alters processing of amyloid precursor protein at the cell surface [abstract]. Neurobiol Aging 1996; 17 Suppl. 4S: S30
74. Cooper S, Kumar R, Higgins R, et al. Safety, tolerability, and pharmacokinetics of SB 202026 in man [abstract]. Neurobiol Aging 1996; 17 Suppl. 4S: S30
75. Rupniak N, Tye S, Iversen S. Comparison of the effects of selective and nonselective muscarinic agonists on cognition and thermoregulation in primates. J Neurol Sci 1992; 110: 222-7
76. 1 agonist improves cognitive performance in rats. Pharmacol Biochem Behav 1995; 51: 667-74
77. Iga Y, Arisawa H, Ise M, et al. Modulation of rhythmical slow activity, long-term potentiation and memory by muscarinic receptor agonists. Eur J Pharmacol 1996; 308: 13-9
78. Kasper SC, Bonate PL, DeLong AF. High-performance liquid chromatographic assay for xanomeline, a specific M-1 agonist, and its metabolite in human plasma. J Chromatography 1995; 669: 397-403
79. 1 receptors. J Pharmacol Exp Ther 1994; 269: 271-81
80. Bymaster F, Wong D, Milch C, et al. Neurochemical effects of the M1 muscarinic agonist xanomeline. J Pharmacol Exp Ther 1994; 269: 282-9
81. Sramek JJ, Hurley DJ, Wardle TS, et al. The safety and tolerance of xanomeline tartrale in patients with Alzheimer's disease. J Clin Pharmacol 1995; 35: 800-6
82. 1 muscarinic agonist. In: Becker R, Giacobini E, editors. Alzheimer disease: from molecular biology to therapy. Boston: Birkhauser, 1996: 311-5
83. Cereda E, Brambilla A, Ezhaya A, et al. Medicinal chemistry of muscarinic agonists for the treatment of dementia disorders. Eur J Drug Metab Pharmacokinet 1994; 19: 179-83
84. Pike B, Hamm R, Zhu J, et al. Chronic post-injury administration of a partial muscarinic M1 agonist improves cognitive outcome and reduces decreases in septal choline acetyltransferase (ChAT) immunoreactivity [abstract]. Soc Neurosci Ahstr 1996; 22: 2154
85. Mayeux R. Therapeutic strategies in Alzheimer's disease. Neurology 1990; 40: 175-80
86. Harrell LE, Callaway R, Morere D, et al. The effect of long-term physostigmine administration in Alzheimer's disease. Neurology 1990; 40: 1350-4
87. Miyamoto M, Narumi S, Nagaoka A, et al. Effects of continuous infusion of cholinergic drugs on memory impairment in rats with basal forebrain lesions. J Pharmacol Exp Ther 1989; 248: 825-35
88. Muramoto O, Sugishita M, Ando K. Cholinergic system and constructional praxis: a further study of physostigmine in Alzheimer's disease. J Neurol Neurosurg Psychiatry 1984; 47: 485-91
89. Gillin J, Sutton L, Ruiz C, et al. The cholinergic rapid eye movement induction test with arecoline in depression. Arch Gen Psychiatry 1991; 48: 264-70
90. Asthana S, Raffaele K, Berardi A, et al. Treatment of Alzheimer disease by continuous intravenous infusion of physostigmine. Alzheimer Dis Assoc Disord 1995; 9: 223-32
91. Schwab BW, Murphy SD. Induction of anticholinesterase tolerance in rats using doses of disulfoton which produce no cholinergic signs. J Toxicol Environ Health 1981; 8: 199-204
92. Sterri SH, Lyngas S, Fonnum F. Toxicity of soman after repetitive injection of sublethal doses in the rat. Acta Pharmacol Toxicol 1980; 46: 1-7